TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1/25/19 16:38 | 1/23/19 | CRIS | Curis Inc | DE | Health | BioPrd | Biological Products, (No Diag | Kunkel Lori Anne | MA | D | S | -16 | 1.05 | 0 | -15 | -40 | 22 | D | |||||||||||||||
10/3/18 17:05 | 10/1/18 | LOXO | Loxo Oncology, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Kunkel Lori Anne | CT | D | S.d | -852 | 170.37 | 0 | -5 | -100 | 0 | D | |||||||||||||||
6/18/18 17:00 | 6/14/18 | LOXO | Loxo Oncology, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Kunkel Lori Anne | CT | D | S.dm | -7,055 | 179.83 | 0 | -39 | -100 | 0 | D | |||||||||||||||
4/24/18 16:30 | 4/20/18 | LOXO | Loxo Oncology, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Kunkel Lori Anne | CT | D | S | -663 | 132.68 | 0 | -5 | -42 | 7 | D | |||||||||||||||
11/6/17 17:03 | 11/2/17 | LOXO | Loxo Oncology, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Kunkel Lori Anne | CT | D | S | -425 | 84.91 | 0 | -5 | -30 | 12 | D | |||||||||||||||
8/23/17 18:35 | 8/22/17 | LOXO | Loxo Oncology, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Kunkel Lori Anne | CT | D | S | -752 | 75.17 | 0 | -10 | -37 | 17 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |